Skip to content
ChickenStockChickenStock
Research226950
OliX Pharmaceuticals logo

OliX Pharmaceuticals (226950) stock

KOSDAQ · Life Sciences Tools & Services

KRW 76,100-5.93%(-4,800)

As of Nov 16, 11:30 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-124.07x

Net loss — not comparable

P/B

7.33x

P/S

127.66x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 2.6 billion-KRW 14 billion-KRW 11 billion-58.0%
Q1 2026Consolidated · Filed May 15, 2026KRW 3.6 billion-KRW 10.8 billion-KRW 9.8 billion+265.8%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 4.5 billion-KRW 8.5 billionKRW 15.4 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 2.9 billion-KRW 8.3 billion-KRW 8.7 billion—
Q2 2025Consolidated · Filed Aug 14, 2025KRW 6.3 billion-KRW 5 billion-KRW 9.2 billion—
Q1 2025Consolidated · Filed May 15, 2025KRW 1 billion-KRW 8.2 billion-KRW 13.3 billion+27.1%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 14.7 billion-KRW 30 billion-KRW 15.7 billion—
FY2024Consolidated · Filed Mar 21, 2025KRW 5.7 billion-KRW 30.9 billion-KRW 40.7 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
7.88%
Of trading value on Nov 13, 2026
Short-sale value
KRW 1.59 billion
Previous 20-day average 7.74%
Net short position
845,138 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
3,736,954 shares
As of Nov 13, 2026 · 16.34% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20267.88%KRW 1.59 billion
Nov 12, 20265.09%KRW 600 million
Nov 11, 20268.11%KRW 1.71 billion
Nov 10, 20266.35%KRW 1.3 billion
Nov 9, 20264.38%KRW 1.15 billion
Nov 6, 20267.08%KRW 2.62 billion
Nov 5, 20264.74%KRW 1.59 billion
Nov 4, 20264.62%KRW 1.75 billion
Nov 3, 202610.42%KRW 2.51 billion
Nov 2, 202611.36%KRW 2.48 billion

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

OliX Pharmaceuticals (226950) stock information

KOSDAQ

OliX Pharmaceuticals (226950) is listed on KOSDAQ. Its market capitalization is about KRW 1.7 trillion. On trailing-twelve-month earnings the P/E ratio is -124.07, and the P/B ratio is 7.33. Return on equity is -5.9%. These figures are computed in-house from official filings and are reference information only.

OliX Pharmaceuticals — frequently asked questions

What is the P/E ratio of OliX Pharmaceuticals (226950)?
On a trailing-twelve-month basis, 226950 trades at a P/E ratio of -124.07. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of OliX Pharmaceuticals?
226950 has a market capitalization of about KRW 1.7 trillion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.